Hafiz Ghafoor, MD
Interventional Cardiology · Worcester, MANPI 1497049852
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (49.3%), travel and lodging and education — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by Medtronic at 40.9% of the total. Reporting peaked in 2024 at $4,190 and has fallen 65.2% since, to $1,460 in 2025.
Across 221 payments — averaging $57.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$5K
- Penumbra, Inc.$2K
- Abiomed$944
- E.r. Squibb & Sons, L.L.C.$501
- Shockwave Medical, Inc$475
- Boston Scientific$399
- plus $3K from 27 others
What the payments were for
- Grants$3493%
- Travel & lodging$5,74845%
- Food & beverage$6,27449%
- Education$3623%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 47 | $5,208 |
| Penumbra, Inc. | 12 | $2,032 |
| Abiomed | 10 | $944 |
| E.r. Squibb & Sons, L.L.C. | 20 | $501 |
| Shockwave Medical, Inc | 6 | $475 |
| Boston Scientific | 3 | $399 |
| Novartis | 17 | $337 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 15 | $327 |
| Johnson & Johnson | 9 | $257 |
| Abbott | 3 | $252 |
| AstraZeneca | 13 | $246 |
| Boehringer Ingelheim | 11 | $222 |
| Surmodics, Inc. | 2 | $204 |
| Baxter Healthcare | 5 | $172 |
| Lantheus Medical Imaging, Inc. | 7 | $169 |
| Amgen | 8 | $153 |
| Amarin Pharma, Inc. | 7 | $127 |
| Edwards Lifesciences | 1 | $113 |
| Astellas Pharma US Inc | 1 | $88 |
| Sanofi-aventis U.S. LLC | 4 | $79 |
| Philips North America LLC | 4 | $75 |
| Angiodynamics, Inc. | 1 | $64 |
| Pfizer | 3 | $53 |
| Z-medica, LLC | 2 | $44 |
| Vifor Pharma, Inc. | 2 | $40 |
| Alnylam Pharmaceuticals Inc. | 1 | $28 |
| GE HealthCare | 1 | $20 |
| Terumo Medical Corporation | 1 | $20 |
| Bayer | 1 | $19 |
| Kestra Medical Technology Services, Inc. | 1 | $18 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $18 |
| AbbVie | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ADVISA DR MRI SURESCAN$2,534
- RUBY Coil$1,594
- VenaSeal$1,305
- Impella$790
- GENERAL ATHERECTOMY$349
- Indigo System$233
- Ensite Cardiac Mapping System$208
- COREVALVE EVOLUT R$139
- Vascular Lithotripsy$135
- CAMZYOS$125
- Sublime 014 Rx PTA Balloon Dilatation Catheter$123
- Sublime Radial Access 018 RX PTA Dilatation Catheter$123
- Sublime Radial Access Guide Sheath$123
- Pounce Thrombectomy System$123
- Pounce Venous Thrombectomy System$123
- Edwards SAPIEN 3 Transcatheter Heart Valve$113
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$109
How this compares
$12,732 in reported general payments places this provider in the 65th percentile of 128 interventional cardiology providers in Massachusetts.
See all interventional cardiology providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 90 | $81,383 |
| EntrestoSacubitril/Valsartan | 24 | $28,132 |
| BrilintaTicagrelor | 35 | $20,315 |
| Ranolazine ErRanolazine | 20 | $1,604 |
| Metoprolol Succinate | 120 | $1,300 |
| Atorvastatin Calcium | 133 | $1,078 |
| Carvedilol | 91 | $606 |
| Cilostazol | 19 | $491 |
| Rosuvastatin Calcium | 39 | $430 |
| Metoprolol Tartrate | 77 | $347 |
| ClopidogrelClopidogrel Bisulfate | 28 | $336 |
| Amlodipine Besylate | 86 | $313 |
| Ezetimibe | 24 | $284 |
| Furosemide | 55 | $270 |
| Amiodarone Hcl | 16 | $224 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $53 | $81,38390 claims |
| NovartisEntresto | $337 | $28,13224 claims |
| AstraZenecaBrilinta | $246 | $20,31535 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 128 interventional cardiology providers in Massachusetts.
Other interventional cardiology in Worcester
- Vaikom MahadevanWorcester$64K
- Nikolaos KakourosWorcester$43K
- Waqas QureshiWorcester$17K
- Krishna Sagar GajulaWorcester$14K
- Eddison RamsaranWorcester$5K
- Eric SecemskyBoston$1.2M
- Darshan DoshiBoston$730K
- Charles GibsonBoston$661K
- Duane PintoBoston$491K
- Robert YehBoston$412K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.